Diabetes screening detector AGEscan

of AGEsglucosebenchtop

Advanced Glycation End of Products Fluorescence Detector Predicting the risk of diabetes in the next 5-10 years; Instant detection, no need for fasting Applicable group: ①Conducting risk assessments for healthy group, high-risk diabetes group, and pre-diabetes group; ②Early screening for undiagnosed people with diabetes and pre-diabetes; Testing principle: AGEscan transmit blue light to enter the crystalline lens of the eye, fluorescent light reflects back from the lens which can be detected by the instrument, auto-fluorescence measurements have been linked to high levels of advanced glycation end-products(AGEs), which accumulate in the presence of diabetes, AGEscan uses the relevant principles to ultimately achieve diabetes risk screening. Clinical significance: athogenic factor affecting the occurrence andsustainable development of diabetes which is associated with proinsulin/insulin. As the age grows, AGEs slowly accumulate in the lens of the eye, and the rate of AGEs is accelerated in insulin resistance, impaired glucose regulation, and diabetic patients. Due to the stable and irreversible characteristics of AGEs, it has superior "memory". Compared with other diabetes monitoring indicators, high AGEs levels can reflect the cumulative damage of abnormal blood sugar and oxidative stress for a longer period of time. It can be used as an early warning signs of pre-diabetes and complications. Application scenarios: Physical Examination Center Health Management Center Endocrinology Department Ophthalmology Department Diabetes Research Institute Primary health careinstitution